All News

colon.Crohns.jpg

JAMA Guideline on the Management of Crohn Disease

Jack Cush, MD

JAMA has published a current Clinical Guidelines Synopsis on the Management of Crohn Disease (CD) in Adults.

Read Article
RheumNow Podcast square

What’s New PsA? (4.3.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and major articles from this week, including FDA safety warnings, reports from AAD, PsA trials.

Read Article
liver.jpg

FDA Safety Warning: Avacopan and Serious Liver Injury

Jack Cush, MD

Yesterday the FDA issued a Drug Safety Communication alerting patients and health care professionals about postmarketing identification of serious (drug induced) liver injury, including fatal cases, associated with the use of avacopan (Tavneos) in patients with ANCA- associated vasculitis.

Read Article
ILD.colors

Review: Rheumatoid Arthritis–Associated Interstitial Lung Disease

Jack Cush, MD

RA-ILD represents the most severe extra-articular manifestation of rheumatoid arthritis, affecting an estimated 1% of the adult population in the US and Northern Europe.

Read Article
RheumNow Podcast square

Moral Distress (3.27.2026)

Jack Cush, MD

Dr. Jack Cush reviews the journal reports and news from RheumNow.com.  This week we discuss moral distress, FM in PsA, Lyme Vax is back & hidden but tangible benefits of the MDHAQ.

Read Article
RheumNow Podcast square

Rheumatology Pitfalls (3.20.2026)

Jack Cush, MD

Dr. Jack Cush reviews the regulatory actions, news and journal reports from this past week on RheumNow.com.

Read Article
Biomarker,genes

Predictors of Response in Lupus

Jack Cush, MD

A systematic review suggests that traditional measures (serologies and disease activity) are superior to biomarkers in predicting response to biologics in systemic lupus erythematosus (SLE) patients. 

Read Article
lab%20-rheumatoid-factor-testing.jpg

Pitfalls of autoimmune serologic testing

Jack Cush, MD

Misuse of laboratory testing may lead to misdiagnoses and mismanagement; this is particulary prevalent when clinicians consider the use of the diagnostic use of  serological autoimmune markers. 

Read Article
Machine learning predicts macrophage activation syndrome in adult Still's disease - 312 AOSD - XGBoost model had 5 predictors: ferritin, splenomegaly, Plt#, cholesterol, & ESR (AUC 0.839, sensit 0.824, specificity 0.710. https://t.co/QrogaCYPCT https://t.co/Z6WgCnFTfx

Links:

Dr. John Cush RheumNow ( View Tweet)
"When there are conflicting diagnostic possibilities, trust your excellent history and physical examination more than laboratory testing and imaging." - Arthur Weinstein, MD

Dr. John Cush RheumNow ( View Tweet)

Advanced Practice Rheum: Rheumatoid & Inflammation Testing In this review, we'll be talking about labs, inflammation, and tests for rheumatoid arthritis. https://t.co/UbEoBz37hT https://t.co/V9WzfRtbFQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Advanced Practice Rheum: Rheumatoid & Inflammation Testing In this review, we'll be talking about labs, inflammation, and tests for rheumatoid arthritis. https://t.co/UlBuUhtB01 https://t.co/09OEk1OLs2

Links:

Dr. John Cush RheumNow ( View Tweet)
A retrospective cohort study of 195 renal Bx from 135 Lupus Nephritis pts, Mod-Severe interstitial fibrosis and tubular atrophy (IFTA) strongly assoc w/non-renal response & ESRD progression (HR 8.9) (also w/ age, SLE duration, prior LN flares, higher chronicity index) https://t.co/773xsk6IHZ
Dr. John Cush RheumNow ( View Tweet)
Predictors of Response in Lupus A systematic review suggests that traditional measures (serologies and disease activity) are superior to biomarkers in predicting response to biologics in systemic lupus erythematosus (SLE) patients. https://t.co/7YuYpoDctR https://t.co/J5VLrkDQ6G

Links:

Dr. John Cush RheumNow ( View Tweet)
A retrospective cohort study of 195 renal Bx from 135 Lupus Nephritis pts, Mod-Severe interstitial fibrosis and tubular atrophy (IFTA) strongly assoc w/non-renal response & ESRD progression (HR 8.9) (also w/ age, SLE duration, prior LN flares, higher chronicity index) https://t.co/3JGLi5R5Fs
Dr. John Cush RheumNow ( View Tweet)
Pitfalls of autoimmune serologic testing Misuse of laboratory testing may lead to misdiagnoses and mismanagement; this is particulary prevalent when clinicians consider the use of the diagnostic use of serological autoimmune markers. https://t.co/QDWTRgdlOh https://t.co/3hvM1OBcMC

Links:

Dr. John Cush RheumNow ( View Tweet)
Prospective multinational cohort of 1180 lupus pts, followed ~2.7 yrs. 37% had renal biopsies (Class III/IV 56%). They achieved mCRR 46%, mPERR 53%, LLDAS 60%, & REMission 46% at least once. renal response highest @ 2 yrs. New organ damage 11% @ 1yr; 33% by 5yr. https://t.co/ugh60M08Xf
Dr. John Cush RheumNow ( View Tweet)
Urinary biomarkers improve w/ anifrolumab in TULIP-LN (lupus nephritis) trial; 112 pts, 197 uriniary proteins assessed. Urinary CD163 and MCP-1 signif improved as early as wk 12. Anifrolumab reduced the proteomic inflammatory signature, regardless of responder status https://t.co/n6fIJVDCN1
Dr. John Cush RheumNow ( View Tweet)
Pitfalls of autoimmune serologic testing Misuse of laboratory testing may lead to misdiagnoses and mismanagement; this is particulary prevalent when clinicians consider the use of the diagnostic use of serological autoimmune markers. https://t.co/VKosO3bVL2 https://t.co/4FTvTcrGJa

Links:

Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study of 180 PMR pts compared dz activity by PMR-AS to Systemic Immune-Inflammation Index (SII = Plts × PMNs/Lymphs) using CBC.48% had mod-hi dz (PMR-AS >=7). SII had moderate correlation with PMR-AS (r = 0.47), possibly useful in monitoring PMR https://t.co/vG1alSdVRU
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×